MediciNova, Inc. operates as a biopharmaceutical company. The Company acquires and develops small molecule therapeutics for the treatment of asthma and COPD, progressive multiple sclerosis, neuropathic pain, methamphetamine addiction, interstitial cystitis, and solid tumor cancers. MediciNova offers its products to the healthcare industry with a focus on the Unites States market.

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-06-11)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MediciNova (MNOV US)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-06-11)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Annual Report to Security Holders (Form ARS | Period ending 2023-12-31)

Current Report (Form 8-K | Period ending 2024-03-26)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)